The direct-to-subject videos facilitate consistent and high quality pulmonary testing across trial sites
Rochester, N.Y. - iCardiac Technologies, Inc., a leading centralized core laboratory specializing in respiratory and cardiac safety studies, announced today that it has launched a Direct-to-Subject Pre-Coaching video tool to help minimize the variability in respiratory test data caused by differences in subject technique and technician coaching. The training videos will be embedded in equipment iCardiac sends to all trial sites and are brief enough to be shown to subjects at the beginning of each testing visit.
The videos will not replace but rather augment the coaching efforts of the site-based pulmonary technicians. By providing guidance and a clear demonstration to each subject shortly before he or she performs a spirometry test, the videos ensure that each subject hears critical information – explained in a clear and consistent way – about how to successfully complete a test. Further, the videos serve to assist and provide a timely refresher to less experienced site technicians on how to effectively coach subjects.
This video-based training standardization platform, now available in 20 languages, has already been deployed by iCardiac on a major global study.
Spirometry measures lung function, which is the amount of air inhaled and the rate at which it is expelled from the lungs. The accuracy and consistency of spirometry test results rely heavily on the patient’s understanding of how to optimally perform the test, and the knowledge and consistency of the medical professional at the site that is coaching that subject through the test.
While performing this test, subjects often make common errors such as a poor breathing effort, incomplete exhalation, or improper use of the equipment. Consistent and effective spirometry testing are critical to the overall outcome and reliability of a clinical trial.
“From the over 250 respiratory clinical trials that we have performed, it is clear that a leading source of test data variability is the variation of coaching styles and knowledge among medical technicians at different clinical sites,” said John Sage, Senior Vice President of Respiratory & eCOA at iCardiac Technologies. “This tool directly and effectively addresses this common issue.”
“We drew upon principles from the fields of cognitive learning, technology-enhanced instruction and psychology to develop this simple but powerful solution,” said Alex Zapesochny, President & CEO of iCardiac Technologies. “And it is being embraced not only by sponsors but also by many site technicians and study subjects for simplifying and improving the overall clinical trial experience.”
About iCardiac Technologies
iCardiac Technologies, Inc. is an industry-leading centralized core laboratory for respiratory and cardiac safety testing services. It has conducted some of the industry’s largest global respiratory studies and has a history of driving innovation across cardiac safety and pulmonary testing. The company serves 8 of the top 10 global pharmaceutical companies, as well as numerous small and mid-sized pharma and biotechnology firms. For more information, please visit: www.icardiac.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.